Which antiarrhythmic drug to choose after electrical cardioversion: A study on non-valvular atrial fibrillation patients

Hye Bin Gwag, Kwang Jin Chun, Jin Kyung Hwang, Seung-Jung Park, June Soo Kim, Kyoung-Min Park, Young Keun On, Hye Bin Gwag, Kwang Jin Chun, Jin Kyung Hwang, Seung-Jung Park, June Soo Kim, Kyoung-Min Park, Young Keun On

Abstract

The relative efficacy of antiarrhythmic drugs (AADs) after electrical cardioversion are not well established. This study aimed to investigate the efficacies of different AADs for maintaining sinus rhythm (SR) after electrical cardioversion for atrial fibrillation (AF). We selected patients from a retrospective registry including patients admitted for cardioversion between January 2012 and June 2016. The primary outcome was time to AF recurrence during the first year after cardioversion. The secondary outcomes included AF recurrence within 1 month, and first readmission due to heart failure, stroke, or additional non-pharmacological rhythm control. A total of 265 patients were divided into the 4 groups according to AAD type: flecainide (n = 33), propafenone (n = 64), amiodarone (n = 128), and dronedarone (n = 40). During the first year after cardioversion, the AF recurrence-free survival was similar between all AAD groups (69.7% vs. 67.2% vs. 71.9% vs. 80.0%, p = 0.439). About half of all recurrences occurred during the first month. There was no difference in any of the secondary outcomes, although the amiodarone group showed a trend toward more non-pharmacological rhythm control. AAD type was not associated with recurrence in multivariate analysis. In this study, half of all patients received amiodarone after electrical cardioversion. Flecainide, propafenone, amiodarone, and dronedarone showed similar efficacies for maintaining SR after electrical cardioversion. Thus, it might be reasonable to reconsider amiodarone use after cardioversion, since it did not show superior efficacy to the other drugs considered and is associated with potential side effects.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Study population.
Fig 1. Study population.
AAD indicates antiarrhythmic drug; ECG, electrocardiogram; MS, mitral stenosis; MVR, mitral valve replacement; PMV, percutaneous mitral balloon valvuloplasty. AADs in the grey box were included in the final analysis.
Fig 2. Kaplan-Meier curve for recurrence of…
Fig 2. Kaplan-Meier curve for recurrence of atrial fibrillation during the first year after electrical cardioversion according to antiarrhythmic drug type.
AF indicates atrial fibrillation; AAD, antiarrhythmic drug. P value as calculated by the log-rank test between the 4 AAD groups. ‘No AAD group’ is shown for reference only.
Fig 3. Cox proportional hazards model for…
Fig 3. Cox proportional hazards model for atrial fibrillation recurrence and additional rhythm control.
The dronedarone group was used as a reference group. Adjusted covariates included sex, cardiomyopathy, chronic obstructive lung disease, coronary artery disease, beta-blocker use, and left atrial volume index. AF indicates atrial fibrillation; CI, confidence interval; HR, hazard ratio.

References

    1. Hohnloser SH, Kuck KH. Randomized trial of rhythm or rate control in atrial fibrillation: the Pharmacological Intervention in Atrial Fibrillation Trial (PIAF). Eur Heart J. 2001;22: 801–802. doi:
    1. Saksena S, Slee A, Waldo AL, Freemantle N, Reynolds M, Rosenberg Y, et al. Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses. J Am Coll Cardiol. 2011;58: 1975–1985. doi:
    1. Hagens VE, Vermeulen KM, TenVergert EM, Van Veldhuisen DJ, Bosker HA, Kamp O, et al. Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation—results from the RAte Control versus Electrical cardioversion (RACE) study. Eur Heart J. 2004;25: 1542–1549. doi:
    1. Schilling RJ. Cardioversion of atrial fibrillation: the use of antiarrhythmic drugs. Heart. 2010;96: 333–338. doi:
    1. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2007: CD005049 doi:
    1. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64: e1–76. doi:
    1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37: 2893–2962. doi:
    1. Alegret JM, Vinolas X, Grande A, Castellanos E, Asso A, Tercedor L, et al. Clinical effectiveness of antiarrhythmic treatment after electrical cardioversion in patients without structural heart disease. Rev Esp Cardiol. 2008;61: 1274–1279.
    1. Chun KJ, Byeon K, Im SI, Park KM, Park SJ, Kim JS, et al. Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. Clin Ther. 2014;36: 1169–1175. doi:
    1. Plewan A, Lehmann G, Ndrepepa G, Schreieck J, Alt EU, Schomig A, et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. Eur Heart J. 2001;22: 1504–1510. doi:
    1. Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 2004;25: 1385–1394. doi:
    1. Bellandi F, Simonetti I, Leoncini M, Frascarelli F, Giovannini T, Maioli M, et al. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol. 2001;88: 640–645.
    1. Qin D, Leef G, Alam MB, Rattan R, Munir MB, Patel D, et al. Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation. J Cardiol. 2016;67: 471–476. doi:
    1. Kim SK, Pak HN, Park JH, Ko KJ, Lee JS, Choi JI, et al. Clinical and serological predictors for the recurrence of atrial fibrillation after electrical cardioversion. Europace. 2009;11: 1632–1638. doi:
    1. Shin DG, Cho I, Hartaigh B, Mun HS, Lee HY, Hwang ES, et al. Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis. Yonsei Med J. 2015;56: 1552–1558. doi:
    1. Kuhn EW, Liakopoulos OJ, Stange S, Deppe AC, Slottosch I, Choi YH, et al. Preoperative statin therapy in cardiac surgery: a meta-analysis of 90,000 patients. Eur J Cardiothorac Surg. 2014;45: 17–26; discussion 26. doi:
    1. Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J, et al. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. J Am Coll Cardiol. 2013;61: 463–468. doi:
    1. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace. 2011;13: 610–625. doi:
    1. Nergardh AK, Rosenqvist M, Nordlander R, Frick M. Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study. Eur Heart J. 2007;28: 1351–1357. doi:
    1. Lindholm CJ, Fredholm O, Moller SJ, Edvardsson N, Kronvall T, Pettersson T, et al. Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil. Heart. 2004;90: 534–538. doi:
    1. Overvad TF, Rasmussen LH, Skjoth F, Overvad K, Albertsen IE, Lane DA, et al. Alcohol intake and prognosis of atrial fibrillation. Heart. 2013;99: 1093–1099. doi:
    1. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310: 2050–2060. doi:

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe